The FDA 510(k) record for K260687 lists Vivachek Biotech (Hangzhou) Co., Ltd. as applicant, with a filing address on Wuzhou Road in the Linping District of Hangzhou, China, and Mark Qian as contact. The device names are VivaChek Blood Glucose and ß-Ketone Dual BLE Monitoring System and VivaChek Blood Glucose and ß-Ketone Dual Monitoring System. The record carries product code NBW, regulation number 862.1345, device class 2, the Clinical Chemistry advisory committee, a Traditional clearance type, a third-party review flag of N, and a decision description of Substantially Equivalent. [1]
The K260687 filing and its decision
The FDA record shows the submission received March 3, 2026, and decided October 9, 2026, with decision code SESE. The statement or summary field reads Summary, and the expedited review flag is blank. The applicant country code is CN and the postal code is 311100. [1]
The FDA 510(k) Premarket Notification database entry for K260687 is the public index page for this notification; the page text captured here consists of navigation and site elements rather than device-specific content. [2]
How the company describes the system
VivaChek's own announcement, dated October 21, 2026, states that the VivaChek Blood Glucose and β-Ketone Dual Monitoring System received 510(k) clearance from the FDA and describes the design as integrating blood glucose and β-ketone testing into a single system, summarized as one meter, one test strip, two results. [4]
A Chinese-language VivaChek article dated October 16, 2026, describes the same clearance and states that the system reads glucose and ketone values from one test strip using roughly 1.6 µL of fingertip blood in 12 seconds. These are the manufacturer's published product descriptions, not FDA-stated performance findings. [7]
Earlier ketone clearance and product context
An earlier FDA clearance letter, K192957, dated June 5, 2020, names Vivachek Biotech (Hangzhou) Co., Ltd. and Mark Qian as Quality Director, for the VivaChek TM Blood Glucose and β-Ketone Monitoring System under regulation number 21 CFR 862.1435, Ketones (nonquantitative) test system, Class I with the exemption limitation at 21 CFR 862.9(c)(5). That letter lists sample volumes of 0.8 µL for blood glucose and 0.8 µL for blood β-ketone, test times of 5 seconds and 10 seconds respectively, and two AAA LR03 1.5V batteries as the power source. [9]
VivaChek's website describes the company as a manufacturer of blood glucose monitoring systems, lateral flow rapid tests, point-of-care analyzers and tests, and PCR kits and instruments, and states that its manufacturing facility is located in Shaoxing, Zhejiang Province. The site lists diabetes care products including blood glucose monitoring systems, multi-function monitoring systems, a professional-use glucose monitoring system and a wireless total solution. [5][8]
The same site states that VivaChek products have been exported to more than 120 countries and that its products are used in more than 1,900 hospitals in China, and that products hold NMPA, CE and FDA certifications. These are company-published statements. [7][8]
Snapshot scope
The linked FDA record collection for this profile contains one 510(k) record, K260687, with a decision count of SESE of one; the smaller record sample likewise contains that single entry. These counts describe the linked filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1]


